



# What if diseases could be detected before presenting clinical symptoms?



## MANAGEMENT

Daniel Skovronsky, MD, PhD  
President and CEO

Alan P. Carpenter Jr., PhD, JD  
Vice President, Business Development,  
Legal and Regulatory Affairs

Franz F. Hefti, PhD  
Chief Scientific Officer

Michael Pontecorvo, PhD  
Vice President, Clinical Development

## BOARD OF DIRECTORS

Daniel Skovronsky, MD, PhD  
President and CEO

William Hamilton, PhD, MBA  
Wharton School, University of Pennsylvania

Matthew Rhodes-Kropf, PhD  
Columbia University; RK Ventures

Ernest Mario, Ph.D.  
Capnia, Inc., CEO & President

Gary J. Kurtzman, M.D.  
Safeguard Scientifics, Vice President

## SCIENTIFIC ADVISORS

Hank F. Kung, PhD  
Chairman, SAB  
Professor of Radiology and Pharmacology,  
University of Pennsylvania

Michael Devous, PhD  
Professor of Radiology and Associate  
Director of Nuclear Medicine Center,  
University of Texas, Southwestern

Joanna Fowler, PhD  
Adjunct Professor, Brookhaven National Labs

Masanori Ichise, MD, FRCPC  
Professor of Clinical Radiology at  
Columbia University College of  
Physicians and Surgeons

Michael Kilbourn, PhD  
Professor of Radiology and Director  
of PET Chemistry Section, University  
of Michigan


James Smith, PhD  
Former EVP, Research and Development,  
EPIX

Henry N. Wagner, Jr., MD  
Professor Emeritus, Johns Hopkins University

At Avid, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an industry-leading management team with extensive imaging and CNS drug development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease and diabetes. This is possible because our molecular imaging compounds may be able to detect the first stages of pathological change, allowing early treatment and management of people at risk — before symptoms of disease can develop.

Avid is a clinical-stage product-focused molecular imaging company with significant expertise and IP in the field of molecular brain imaging. Avid has developed proprietary targeting agents to image amyloid plaques and is currently testing these compounds in clinical trials for the detection of Alzheimer's disease. Avid has demonstrated the proof of mechanism in human trials with these agents. The Avid team is also developing novel agents targeted to the vesicular monoamine transporter (VMAT-2) to image pathology in dementia with Lewy bodies (DLB), Parkinson's disease (PD), and has recently started a research project in diabetes mellitus (DM). These agents have the potential to revolutionize early diagnosis and monitoring of disease.

## PREVALENCE OF NEURODEGENERATIVE DISEASE IN THE US



Avid's imaging compounds are targeted to more than 80% of the rapidly growing neurodegeneration population. The prevalence of AD alone may soar to 7.7 million people by 2030 and 16 million by the middle of the century.

Sources: Alzheimer's Association, National Parkinson's Foundation, Lewy Body Dementia Association

## CLINICAL PROGRAMS

### AVID'S DEVELOPMENT PIPELINE

Avid is a leader in the development of AD imaging agents and has multiple promising PET and SPECT compounds in clinical trials. Avid also works with multiple global pharmaceutical partners in both PET and SPECT imaging. Avid has a pipeline of research leads through its continued collaborations with the University of Pennsylvania and other major academic research institutions.

#### Alzheimer's disease (AD)

Early intervention with the four approved drugs commonly used to treat AD results in qualitative and quantitative patient improvements. New treatment methods for slowing or reversing the deposition of insoluble amyloid in AD patients' brains are the subject of intensive clinical research. Avid's  $\beta$ -amyloid imaging agents may aid in the identification of patients who have the best chance of responding to these new treatments.

#### Parkinson's disease (PD)

PD is diagnosed by clinical criteria which can be inaccurate, particularly early in the disease course. Definitive diagnosis of PD currently requires verification of degeneration of dopaminergic neurons in the brain at autopsy. Avid's agents allow *in vivo* imaging of dopaminergic degeneration and may facilitate early diagnosis and monitoring of PD patients.

#### Dementia with Lewy bodies (DLB)

DLB symptoms (progressive cognitive decline combined with variations in alertness and attention, hallucinations, and Parkinson-like motor symptoms), are caused by the build-up of Lewy bodies composed of the alpha-synuclein protein which accumulates inside neurons in memory and motor-control areas of the brain. Lewy bodies can also be

#### Dementia with Lewy bodies (DLB) (continued)

found in the brains of people with Parkinson's and Alzheimer's diseases, suggesting that DLB is related to these and that an individual can have both amyloid and alpha-synuclein based dementias. Imaging agents such as those under development by Avid may allow the differential diagnosis of DLB from AD and lead to the selection of appropriate therapeutics.

#### Diabetes mellitus (DM)

Type 1 and Type 2 diabetes affect 21 million people in the US alone. Diabetes results from an imbalance between insulin production and metabolic demand, leading to uncontrolled blood glucose levels, and to illnesses including heart and kidney failure. The loss of the insulin-producing beta cells of the pancreas is at the core of diabetes. Avid has identified imaging compounds which may allow the *in vivo* imaging of beta cells and provide an earlier signal of a pre-diabetic state than current diagnostic methods.

## INTELLECTUAL PROPERTY

Avid has exclusive worldwide licenses to several patents and patent applications covering the AD products from the University of Pennsylvania, and it has an exclusive license to the IP covering the Parkinson's and Lewy body imaging compounds from the University of Pennsylvania and the University of Michigan. Avid also has rights to a pipeline of radiopharmaceuticals for other indications under investigation through sponsored research agreements with the University of Pennsylvania.

## INVESTORS

Avid's investors include AllianceBernstein, Safeguard Scientifics, Pfizer Strategic Investment Group, Lilly Ventures, RK Ventures and BioAdvance. Avid closed a \$25M funding round in May 2007.